Healthcare Costs
-
Caught my eye, Generics, Healthcare Costs, ICER, Inflation Reduction Act, Medicaid, Medicare Negotiation, Medicare Part D, Orphan Drugs, State-based Reform, ValueCaught my eye — 03/07/25
Read more: Caught my eye — 03/07/25Tuesday morning, I spent the first half of the day convinced it was Wednesday, and yet, despite that mental setback, the rest of the week has flown by. Feels like a win. Killing me softly. Overall, glad to see the stories recognizing how the uncertainty of federal research dollars is impacting NIH summer internships, graduate…
-
Caught my eye — 2/28/25
Read more: Caught my eye — 2/28/25Tariffic. This week Eli Lilly announced they were investing at least $27 billion in US manufacturing, which is pretty cool. Was it to buy favor with the new Administration? It certainly does not hurt. I get the allure of manufacturing in the United States. If a country wanted to hurt us, they could stop sending…
-
Caught my eye — 2/21/25
Read more: Caught my eye — 2/21/25Discontinued: A flu vaccination campaign got pulled by the Department of Health and Human Services (HHS). It is off the air and the website was taken offline and now directs users to older information and not the new campaign (“Wild to Mild”.) 1 in 5. Did you know that 1 in 5 people in the…
-
Caught my eye, Healthcare Costs, ICER, Inflation Reduction Act, Medicare Negotiation, Medicare Part D, Obesity, ValueCaught my eye — 2/14/25
Read more: Caught my eye — 2/14/25Roses are red. Violets are blue. I love health policy, how about you? Public Health Gap: This week a poll found that a quarter of Americans see healthcare access and affordability as their top public health concern and think it would be best solved on the federal level. Among Democrats, 32% had it as their…
-
340B, Caught my eye, Drug Prices, Healthcare Costs, Inflation Reduction Act, Medicare Negotiation, Medicare Part D, Pharmacy Benefit ManagersCaught my eye — 1/10/25
Read more: Caught my eye — 1/10/25There are some weeks where your long-term success could be impacted if you’re not on top of what’s happening, this isn’t one of those weeks. But these things are cumulative so, if need help on the regular with strategy and health policy (like figuring out what you need to pay attention to, help understanding the…
-
Caught my eye — 12/6/24
Read more: Caught my eye — 12/6/24When your job is to stay on top of the news but you also just want to turtle a little bit, there are challenges that eventually have to be faced. Skimming the news, here is what caught my eye… 340B Bonanza. I have been devouring the 340B coverage of J&J, Lilly and BMS suing the…
-
Caught my eye, Drug Prices, Healthcare Costs, Inflation Reduction Act, Medicare Negotiation, Medicare Part DCaught my eye — 11/22/24
Read more: Caught my eye — 11/22/24As we look ahead to next week and Thanksgiving, I have to say thank you to you for subscribing and reading. I got the stuffing knocked out of me this summer but knowing that this group of subscribers hangs in there and continues to read is nice. As I look ahead to the next year,…
-
Caught my eye — 11/1/24
Read more: Caught my eye — 11/1/24As I write this, the elementary school across the street has Thriller playing at the 5th grade Halloween party happening in the parking lot. Things change and they stay the same. Not the worst reminder this week. Waiting. Payment rules expected from the Centers for Medicare & Medicaid Services plus maybe eventually the Medicare Transaction…
-
Biosimilars, Caught my eye, CMMI, Drug Prices, Employers, Healthcare Costs, Obesity, Pharmacy Benefit ManagersCaught my eye — 9/27/24
Read more: Caught my eye — 9/27/24If you haven’t trained your teams on Medicare Part D changes for 2025, hop to it. Or reach out to me. These are January 1 issues and we’re about to hit October…. Let me clear my throat. The STAT news breaking news headline read “Sanders says pharmacy benefit managers (PBMs) won’t penalize Novo for cutting…
-
340B, Caught my eye, Drug Prices, Healthcare Costs, Inflation Reduction Act, Medicare Advantage, Medicare Negotiation, Medicare Part DCaught my eye — 9/20/24
Read more: Caught my eye — 9/20/24Adding On. So glad to see this research from Avalere conducted on behalf of the Community Oncology Alliance (COA) on the impact of the Inflation Reduction Act (IRA) negotiation on Medicare Part B provider reimbursement. While in Medicare Part D, negotiated prices do not factor into Average Manufacturer Price, the legislation is silent on whether…
Latest news
- Caught my eye — 03/28/25
- Caught my eye — 3/21/25
- Caught my eye — 3/14/25
- Caught my eye — 03/07/25
- Caught my eye — 2/28/25
Categories
- 340B (33)
- Affordable Care Act (4)
- Alzheimer's (5)
- Biosimilars (20)
- Caught my eye (61)
- Cell and Gene (1)
- Chevron Deference (2)
- CMMI (10)
- Copay Accumulators (6)
- COVID (2)
- Drug Prices (30)
- Drug shortages (8)
- DTC (2)
- Employers (7)
- Generics (5)
- Health Equity (3)
- Healthcare Costs (28)
- ICER (9)
- Importation (2)
- Inflation Reduction Act (45)
- Insulin (4)
- IP (3)
- Long term care (1)
- Medicaid (6)
- Medicare Advantage (15)
- Medicare Negotiation (48)
- Medicare Part D (44)
- Medicare Transaction Facilitator (2)
- Medicare Transaction Facilitator (7)
- Obesity (20)
- On the Horizon (1)
- Orphan Drugs (3)
- Pharmacy Benefit Managers (28)
- Reference Pricing (5)
- State-based Reform (14)
- Supply Chain (1)
- Uncategorized (4)
- Utilization Management (1)
- Vaccines (4)
- Value (12)